Physician profile
Frank Martinez
NPI 1235237553
$5,224.15
in general payments reported to CMS, 2019-2025
36 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,403 · 2020: $159 · 2021: $1,073 · 2022: $560 · 2023: $374 · 2024: $512 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,029.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $750.30 | 2019-2024 | |
| Pfizer INC. | $721.84 | 2019-2025 | |
| Novo Nordisk INC | $639.22 | 2019-2025 | Ozempic, Wegovy |
| Amgen INC. | $425.50 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $409.84 | 2019-2021 | |
| Glaxosmithkline, LLC. | $314.64 | 2019-2024 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $264.17 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $238.95 | 2019-2021 | |
| Lilly USA, LLC | $213.08 | 2019-2024 | Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $162.27 | 2019 | |
| Amarin Pharma, INC. | $143.90 | 2019-2022 | |
| Allergan, INC. | $134.61 | 2019-2020 | |
| Abbott Laboratories | $86.04 | 2019-2023 | Proclaim |
| Merck Sharp & Dohme LLC | $82.47 | 2019-2023 | Belsomra, Steglujan, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.86 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.89 | 2019-2024 | Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $68.35 | 2021 | |
| Nevro Corp. | $65.51 | 2022-2024 | Senza |
| Dexcom, INC. | $54.28 | 2021-2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $40.90 | 2024 | Gemtesa |
| Esperion Therapeutics, INC. | $27.38 | 2021 | |
| Phathom Pharmaceuticals, INC. | $18.59 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $18.10 | 2019 | |
| Corcept Therapeutics | $17.81 | 2019 | |
| Currax Pharmaceuticals LLC | $17.52 | 2025 | Contrave |
| Horizon Therapeutics Plc | $16.98 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.29 | 2021 | |
| Astellas Pharma US INC | $16.17 | 2023 | Myrbetriq |
| Neuronetics, INC. | $15.94 | 2019 | |
| Genentech USA, INC. | $15.88 | 2019 | |
| Lifescan, INC. | $15.26 | 2019 | |
| Radius Health, INC. | $14.33 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.05 | 2019 | |
| Shire North American Group INC | $12.90 | 2019 | |
| Shionogi INC | $11.81 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.